GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » G Medical Innovations Holdings Ltd (OTCPK:GMVDF) » Definitions » Net Income

G Medical Innovations Holdings (G Medical Innovations Holdings) Net Income : $-24.63 Mil (TTM As of Dec. 2022)


View and export this data going back to 2017. Start your Free Trial

What is G Medical Innovations Holdings Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. G Medical Innovations Holdings's Net Income for the six months ended in Dec. 2022 was $-11.61 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2022 was $-24.63 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. G Medical Innovations Holdings's Earnings per Share (Diluted) for the six months ended in Dec. 2022 was $-7.57.


G Medical Innovations Holdings Net Income Historical Data

The historical data trend for G Medical Innovations Holdings's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G Medical Innovations Holdings Net Income Chart

G Medical Innovations Holdings Annual Data
Trend Sep16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income
Get a 7-Day Free Trial -16.98 -15.51 -12.54 -14.76 -24.63

G Medical Innovations Holdings Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.56 -4.69 -10.06 -13.02 -11.61

G Medical Innovations Holdings Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

G Medical Innovations Holdings's Net Income for the fiscal year that ended in Dec. 2022 is calculated as

Net Income(A: Dec. 2022 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-13.942+-0.016+-11.108+0.437
=-24.63

G Medical Innovations Holdings's Net Income for the quarter that ended in Dec. 2022 is calculated as

Net Income(Q: Dec. 2022 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.668+-0.003+0+-10.937
=-11.61

Net Income for the trailing twelve months (TTM) ended in Dec. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-24.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


G Medical Innovations Holdings  (OTCPK:GMVDF) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

G Medical Innovations Holdings's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


G Medical Innovations Holdings Net Income Related Terms

Thank you for viewing the detailed overview of G Medical Innovations Holdings's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


G Medical Innovations Holdings (G Medical Innovations Holdings) Business Description

Traded in Other Exchanges
N/A
Address
5 Oppenheimer Street, Rehovot, ISR, 7670105
G Medical Innovations Holdings Ltd is a mobile health (mHealth), telemedicine solutions, and monitoring service platforms. It develops and markets clinical and consumer medical-grade health monitoring solutions and offers end-to-end support for e-health projects. The company offers a suite of both consumer and clinical grade products and platforms which are positioned to reduce inefficiencies in healthcare delivery, improve access, reduce costs, increase the quality of care, and make healthcare more personalized and precise. Its operating segment includes Products, Patient Services, and Covid-19 testing. The company generates maximum revenue from the Patient Services segment.
Executives
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022